Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Clin Pharmacol Ther. 2017 May 26;102(3):511–519. doi: 10.1002/cpt.644

Table 1.

Baseline patient characteristics

Characteristic 2 hour cryotherapy
(n = 73)
6 hour cryotherapy
(n = 73)
Age
Mean (sd) 58.3 (8.1) 58.1 (7.2)
Median (min – max) 60 (38 – 71) 59 (35 – 72)
< 60 35 (48.0) 39 (53.4)
60 – 65 23 (31.5) 27 (37.0)
> 65 15 (20.5) 7 (9.6)

Gender
Male (%) 46 (63.0) 44 (60.3)
Female (%) 27 (37.0) 29 (39.7)

Race
White (%) 66 (90.4) 61 (83.6)
Other (%) 7 (9.6) 12 (16.4)

Risk group
Standard (%) 44 (60.3) 45 (61.6)
Intermediate (%) 13 (17.8) 21 (28.8)
High (%) 13 (17.8) 6 (8.2)
Missing (%) 3 (4.1) 1 (1.4)

Melphalan dose
140 mg/m2 (%) 12 (16.4) 11 (15.1)
200 mg/m2 (%) 61 (83.6) 62 (84.9)

CD34+ stem cell dose (106 cells/kg)
Mean (sd) 4.6 (2.2) 4.7 (2.1)
Median (min – max) 4.2 (2.0 – 15.7) 4.1 (1.9 – 11.7)

Creatinine Clearance (mL/min)
Mean (sd) 87.4 (42.5) 87.6 (40.7)
Median (min – max) 85.2 (7.39 – 196.5) 90.6 (0.2 – 168.7)

Hemoglobin (g/dL)
Mean (sd) 11.0 (1.7) 10.9 (1.6)
Median (min – max) 10.9 (7.1 – 14.8) 10.9 (7.0 – 14.7)

Fat Free Mass (kg)
Mean (sd) 57.7 (13.3) 58.3 (11.9)
Median (min – max) 61.5 (31.3 – 81.9) 60.0 (35.2 – 80.4)

SLC7A5 genotype (rs4240803)
MAF (p value) 0.31 (0.996) 0.3 (0.908)
M/M (%) 24 (32.9) 26 (35.6)
M/m (%) 21 (28.8) 25 (34.2)
m/m (%) 5 (6.8) 4 (5.5)
Missing (%) 23 (31.5) 18 (24.7)

Risk groups were defined by cytogenetic analysis of diagnostic bone marrow samples as defined by Mikhael and colleagues (19). For SLC7A5 genotyping, MAF, minor allele frequency; M, major allele; m, minor allele; Two-tailed χ2 tests were used to analyze the differences between the actual and predicted (Hardy-Weinberg equilibrium) genotype frequency, and the p-values for these are presented.